Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Bilal A Siddiqui; Jinesh S Gheeya; Rohit Goswamy; Tharakeswara K Bathala; Devaki Shilpa Surasi; Jianjun Gao; Amishi Shah; Matthew T Campbell; Pavlos Msaouel; Sangeeta Goswami; Jennifer Wang; Amado J Zurita; Eric Jonasch; Paul G Corn; Ana M Aparicio; Arlene O Siefker-Radtke; Padmanee Sharma; Sumit K Subudhi; Nizar Tannir

doi:10.1136/jitc-2021-002850

Article info

PDF

PDF +
Supplementary
Material

XML

Clinical/translational cancer immunotherapy

Original research

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Authors

Bilal A Siddiqui Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Jinesh S Gheeya Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articles Google scholar articles
Rohit Goswamy Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, Texas, USA PubMed articles Google scholar articles
Tharakeswara K Bathala Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Devaki Shilpa Surasi Department of Nuclear Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Jianjun Gao Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Amishi Shah Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Matthew T Campbell Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Pavlos Msaouel Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Sangeeta Goswami Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Jennifer Wang Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Amado J Zurita Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Eric Jonasch Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Paul G Corn Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Ana M Aparicio Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Arlene O Siefker-Radtke Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Padmanee Sharma Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USADepartment of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Sumit K Subudhi Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles
Nizar Tannir Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA PubMed articles Google scholar articles

Citation

Siddiqui BA, Gheeya JS, Goswamy R, et al

Durable responses in patients with genitourinary cancers following immune checkpoint therapy rechallenge after moderate-to-severe immune-related adverse events

Journal for ImmunoTherapy of Cancer 2021;9:e002850. doi: 10.1136/jitc-2021-002850

Online issue publication

November 02, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

Log in using your username and password

Main menu

Log in using your username and password

You are here

Authors

Citation

Request permissions

Copyright information

Read the full text or download the PDF:

Log in using your username and password